Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

Gilles Freyer,Anne Floquet,Olivier Tredan,Aurore Carrot,Carole Langlois-Jacques,Jonathan Lopez,Frédéric Selle,Cyril Abdeddaim,Alexandra Leary,Coraline Dubot-Poitelon,Michel Fabbro,Laurence Gladieff,Michele Lamuraglia

DOI: https://doi.org/10.1038/s41467-024-45974-w

IF: 16.6

2024-03-06

Nature Communications

Abstract:Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. This open-label phase 2 study (NCT04015739) aimed to assess activity and safety of this triple combination in female patients with relapsed high-grade AOC following prior platinum-based therapy. Patients were treated with olaparib (300 mg orally, twice daily), the bevacizumab biosimilar FKB238 (15 mg/kg intravenously, once-every-3-weeks), and durvalumab (1.12 g intravenously, once-every-3-weeks) in nine French centers. The primary endpoint was the non-progression rate at 3 months for platinum-resistant relapse or 6 months for platinum-sensitive relapse per RECIST 1.1 and irRECIST. Secondary endpoints were CA-125 decline with CA-125 ELIMination rate constant K (KELIM-B) per CA-125 longitudinal kinetics over 100 days, progression free survival and overall survival, tumor response, and safety. Non-progression rates were 69.8% (90%CI 55.9%-80.0%) at 3 months for platinum-resistant relapse patients (N = 41), meeting the prespecified endpoint, and 43.8% (90%CI 29.0%-57.4%) at 6 months for platinum-sensitive relapse (N = 33), not meeting the prespecified endpoint. Median progression-free survival was 4.1 months (95%CI 3.5–5.9) and 4.9 months (95%CI 2.9–7.0) respectively. Favorable KELIM-B was associated with better survival. No toxic deaths or major safety signals were observed. Here we show that further investigation of this triple combination may be considered in AOC patients with platinum-resistant relapse.

multidisciplinary sciences

What problem does this paper attempt to address?

The paper aims to address the issue of recurrence in patients with advanced ovarian cancer (AOC) after platinum-based chemotherapy. Specifically, the study evaluates the efficacy and safety of a combination therapy involving bevacizumab, olaparib, and durvalumab in patients with recurrent high-grade ovarian cancer. The primary endpoints of the study are the 3-month progression-free rate in platinum-resistant recurrent patients and the 6-month progression-free rate in platinum-sensitive recurrent patients. Additionally, the study explores secondary endpoints, including CA-125 reduction, progression-free survival (PFS), overall survival (OS), tumor response, and safety.

The study results show that in platinum-resistant recurrent patients, the 3-month progression-free rate was 69.8%, reaching the preset target; whereas in platinum-sensitive recurrent patients, the 6-month progression-free rate was 43.8%, not reaching the preset target. The median progression-free survival was 4.1 months and 4.9 months, respectively. The study also found that the KELIM-B value was associated with better survival outcomes. Furthermore, the safety of the combination therapy was good, with no severe toxicity or new safety signals observed. The study also explored the role of predictive biomarkers, particularly KELIM-B and T-cell inflammation gene expression profile (TIS), which may help identify patients most likely to benefit from the treatment.